NEW YORK (GenomeWeb) – Biocept said today that it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately 990,000 shares of its common stock at a price of $2.25 per share, resulting in gross proceeds of approximately $2.2 million.

Maxim Group is acting as the lead placement agent and Dawson James Securities is co-placement agent for the offering, which is expected to close on or about January 23, subject to the satisfaction of customary closing conditions.